Anti-TSLP/IL-13 antibody

Anti-TSLP/IL-13 antibodies represent an investigational class of bispecific monoclonal antibodies designed to simultaneously target thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13). TSLP is an upstream epithelial-derived alarmin that plays a critical role in initiating and driving type 2 inflammatory responses, while IL-13 is a key downstream effector cytokine that mediates tissue remodeling, airway hyperresponsiveness, and goblet cell hyperplasia. By dual-targeting both the initiation (TSLP) and effector (IL-13) pathways of type 2 inflammation, these bispecific antibodies aim to provide synergistic and more comprehensive therapeutic efficacy compared to monotherapies targeting either pathway alone. Several candidates in this class, such as lunsekimig (SAR443765) and BEL512 (CM512), are currently in clinical development for the treatment of moderate-to-severe type 2 inflammatory diseases, including asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis.